Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 03 2021 - 4:05PM
Prothena Announces Inducement Grant Under Nasdaq Listing Rule
5635(c)(4)
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
company with a robust pipeline of novel investigational
therapeutics built on protein dysregulation expertise, today
announced that in connection with hiring a new employee, the
compensation committee of the Company’s board of directors granted
the individual hired by the Company an option to purchase 75,000
ordinary shares of the Company. The option has an exercise price
per share equal to $69.88, which was the closing trading price on
September 1, 2021, the date of the grant. The option will vest over
four years, with 25% of the underlying shares vesting on the
one-year anniversary of the date of grant and 1/48th of the
underlying shares vesting monthly thereafter over 36 months. The
option was granted pursuant to the Company’s 2020 Employment
Inducement Incentive Plan, which was approved by the Company’s
board of directors under Rule 5635(c)(4) of The Nasdaq Global
Market for equity grants to induce new employees to enter into
employment with the Company.
About Prothena
Prothena Corporation plc is a late-stage
clinical company with a robust pipeline of novel investigational
therapeutics built on protein dysregulation expertise with the
potential to change the course of devastating rare peripheral
amyloid and neurodegenerative diseases. Fueled by its deep
scientific expertise built over decades of research, Prothena is
advancing a pipeline of therapeutic candidates for a number of
indications and novel targets for which its ability to integrate
scientific insights around neurological dysfunction and the biology
of misfolded proteins can be leveraged. Prothena’s pipeline
includes both wholly-owned and partnered programs being developed
for the potential treatment of diseases including AL amyloidosis,
ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a
number of other neurodegenerative diseases. For more information,
please visit the Company’s website at www.prothena.com and follow
the Company on Twitter @ProthenaCorp.
Media & Investors:Jennifer
Zibuda, Director, Investor Relations &
Communications650-837-8535, jennifer.zibuda@prothena.com
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Historical Stock Chart
From Jul 2023 to Jul 2024